Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | CHIEF STRATEGY OFFICER | January 22, 2026 | January 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date January 22, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,500 |
Reported balance
After 2026-01-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-24 · Exercise / conversion · Acquired 2,500 · Balance 2,500 |
| Common StockSEC Table I · non-derivative | Direct | 1,384 |
Reported balance
After 2026-01-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-01-24 · Tax withholding · Disposed 1,116 · Balance 1,384 F1: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. |
| Common StockSEC Table I · non-derivative | Direct | 2,600 |
Reported balance
After 2026-01-25 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-01-25 · Exercise / conversion · Acquired 2,600 · Balance 2,600 |
| Common StockSEC Table I · non-derivative | Direct | 1,474 |
Reported balance
After 2026-01-25 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-01-25 · Tax withholding · Disposed 1,126 · Balance 1,474 F1: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $36.76 · Expires 2036-01-22 | Direct | 42,600 |
Reported balance
After 2026-01-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-22 · Grant · Acquired 42,600 · Balance 42,600 F2: The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,200 |
Reported balance
After 2026-01-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-22 · Grant · Acquired 12,200 · Balance 12,200 F3: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,000 |
Reported balance
After 2026-01-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-24 · Exercise / conversion · Disposed 2,500 · Balance 5,000 F4: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 7,800 |
Reported balance
After 2026-01-25 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-25 · Exercise / conversion · Disposed 2,600 · Balance 7,800 F5: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date.
F2: The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
F3: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
F4: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
F5: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 25, 2026 Filed Jan 26, 2026 21:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001821460-26-000002 · form4-01262026_090155.xml · derivative · entry 8 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.exercise_price: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.exercise_date: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F5 · derivative.expiration_date: This award of restricted stock units was previously granted on January 25, 2025. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 25, 2026 Filed Jan 26, 2026 21:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 1,126 | $36.82 | $41,459.32 |
DisclosureSEC source: 0001821460-26-000002 · form4-01262026_090155.xml · nonDerivative · entry 4 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,474 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 25, 2026 Filed Jan 26, 2026 21:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001821460-26-000002 · form4-01262026_090155.xml · nonDerivative · entry 3 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 21:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001821460-26-000002 · form4-01262026_090155.xml · derivative · entry 7 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_price: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.expiration_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 21:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 1,116 | $36.82 | $41,091.12 |
DisclosureSEC source: 0001821460-26-000002 · form4-01262026_090155.xml · nonDerivative · entry 2 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,384 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 24, 2026 Filed Jan 26, 2026 21:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001821460-26-000002 · form4-01262026_090155.xml · nonDerivative · entry 1 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 12,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001821460-26-000002 · form4-01262026_090155.xml · derivative · entry 6 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,200 Underlying: Common Stock · 12,200 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F3 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F3 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 22, 2027, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:48 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 42,600 | $0.00 Strike: $36.76 | $0.00 |
DisclosureSEC source: 0001821460-26-000002 · form4-01262026_090155.xml · derivative · entry 5 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,600 Underlying: Common Stock · 42,600 shares Expires 2036-01-22 F2 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 22, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 17:51 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Units · Derivative | 10,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002155 · form4-01282025_050131.xml · derivative · entry 5 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,400 Underlying: Common Stock · 10,400 shares Expires not disclosed F4 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F4 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 25, 2025 Filed Jan 28, 2025 17:51 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 36,500 | $0.00 Strike: $38.01 | $0.00 |
DisclosureSEC source: 0001415889-25-002155 · form4-01282025_050131.xml · derivative · entry 4 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,500 Underlying: Common Stock · 36,500 shares Expires 2035-01-25 F3 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 25, 2026, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 17:51 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002155 · form4-01282025_050131.xml · derivative · entry 3 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 17:51 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Tax withholdingCommon Stock | 865 | $38.01 | $32,878.65 |
DisclosureSEC source: 0001415889-25-002155 · form4-01282025_050131.xml · nonDerivative · entry 2 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,635 F1 · security: Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 17:51 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002155 · form4-01282025_050131.xml · nonDerivative · entry 1 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:54 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantRestricted Stock Unit · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001870 · form4-01262024_090117.xml · derivative · entry 2 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.exercise_date: The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. F2 · derivative.expiration_date: The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:54 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 47,750 | $0.00 Strike: $30.69 | $0.00 |
DisclosureSEC source: 0001415889-24-001870 · form4-01262024_090117.xml · derivative · entry 1 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,750 Underlying: Common Stock · 47,750 shares Expires 2034-01-24 F1 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 21:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 38,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001415889-22-012041 · form4-12052022_041201.xml · derivative · entry 4 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,729 Underlying: Common Stock · 38,000 shares Expires 2027-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options vests in five equal annual installments beginning on October 1, 2018. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 21:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 920 | $60.71 | $55,854.03 |
DisclosureSEC source: 0001415889-22-012041 · form4-12052022_041201.xml · nonDerivative · entry 3 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.67 to $60.77. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 21:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 37,080 | $60.12 | $2,229,245.89 |
DisclosureSEC source: 0001415889-22-012041 · form4-12052022_041201.xml · nonDerivative · entry 2 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.67 to $60.66. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 21:10 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 38,000 | $8.22 | $312,360.00 |
DisclosureSEC source: 0001415889-22-012041 · form4-12052022_041201.xml · nonDerivative · entry 1 Serafin Andrew · CIK 0001821460 · CHIEF STRATEGY OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 23:42 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionSeries C Preferred Stock · Derivative | 51,681 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023394 · doc4.xml · derivative · entry 4 Serafin Andrew · CIK 0001821460 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,871 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering. F3 · shares: Includes 661 shares received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering. F3 · derivative.underlying_shares: Includes 661 shares received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 23:42 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionSeries A Preferred Stock · Derivative | 207,869 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023394 · doc4.xml · derivative · entry 3 Serafin Andrew · CIK 0001821460 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,214 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering. F2 · shares: Includes 7,869 shares received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering. F2 · derivative.underlying_shares: Includes 7,869 shares received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 23:42 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionCommon Stock | 6,871 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-023394 · doc4.xml · nonDerivative · entry 2 Serafin Andrew · CIK 0001821460 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 23:42 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionCommon Stock | 32,214 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-023394 · doc4.xml · nonDerivative · entry 1 Serafin Andrew · CIK 0001821460 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a one-for-one basis into Common stock upon the closing of the Issuer's initial public offering. Read SEC document |
| August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionSeries C Preferred Stock · Derivative | 51,021 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024370 · doc4a.xml · derivative · entry 3 Serafin Andrew · CIK 0001821460 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,653.98 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F3 · derivative.underlying_shares: Includes 443.27 shares of common stock received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020. Read SEC document |
| August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionSeries A Preferred Stock · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-024370 · doc4a.xml · derivative · entry 2 Serafin Andrew · CIK 0001821460 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,039.05 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.exercise_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F1 · derivative.expiration_date: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. F2 · derivative.underlying_shares: Includes 2,693.34 shares of common stock received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020. Read SEC document |
| August 21, 2020 Filed Sep 4, 2020 21:19 UTC Amendment | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | ConversionCommon Stock | 33,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-024370 · doc4a.xml · nonDerivative · entry 1 Serafin Andrew · CIK 0001821460 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock automatically converted on a 8.215-for-one basis into common stock upon the closing of the Issuer's initial public offering, with any fractional shares resulting from the conversion of the aggregate preferred stock held by the reporting person canceled in exchange for cash. Read SEC document |
| August 18, 2020 Filed Aug 21, 2020 00:05 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 81,875 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023130 · doc4.xml · derivative · entry 1 Serafin Andrew · CIK 0001821460 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,875 Underlying: Common Stock · 81,875 shares Expires 2030-08-18 F1 · derivative.exercise_date: The stock option shall vest in five equal annual installments beginning on August 21, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.